Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer

被引：5

作者：

Cao, Yi ^{[1
,2
]}

Li, Yunjin ^{[1
,2
]}

Liu, Ruijie ^{[1
]}

Zhou, Jianhua ^{[1
,2
]}

Wang, Kuansong ^{[1
,2
]}

机构：

[1] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Peoples R China

[2] Cent South Univ, Sch Basic Med Sci, Dept Pathol, Changsha 410008, Peoples R China

来源：

CANCERS | 2023年 / 15卷 / 09期

基金：

中国国家自然科学基金;

关键词：

HER2-positive breast cancer; targeted therapy; resistance; anti-resistance; TRASTUZUMAB RESISTANCE; PROMOTES RESISTANCE; MONOCLONAL-ANTIBODY; SPLICE VARIANT; PHASE-II; HER2; GROWTH; EXPRESSION; LAPATINIB; CELLS;

D O I：

10.3390/cancers15092568

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The amplification of epidermal growth factor receptor 2 (HER2) is associated with a poor prognosis and HER2 gene is overexpressed in approximately 15-30% of breast cancers. In HER2positive breast cancer patients, HER2-targeted therapies improved clinical outcomes and survival rates. However, drug resistance to anti-HER2 drugs is almost unavoidable, leaving some patients with an unmet need for better prognoses. Therefore, exploring strategies to delay or revert drug resistance is urgent. In recent years, new targets and regimens have emerged continuously. This review discusses the fundamental mechanisms of drug resistance in the targeted therapies of HER2positive breast cancer and summarizes recent research progress in this field, including preclinical and basic research studies.

引用

页数：27

共 137 条

[1] A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer [J].

Balch, Sara M. ;

Vaz-Luis, Ines ;

Li, Tianyu ;

Tayob, Nabihah ;

Jain, Esha ;

Helvie, Karla ;

Buendia-Buendia, Jorge E. ;

Shannon, Erin ;

Isakoff, Steven J. ;

Tung, Nadine M. ;

Krop, Ian E. ;

Lin, Nancy U. ;

Wagle, Nikhil ;

Freedman, Rachel A. .

BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) :411-423

[2] Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study [J].

Banerji, Udai ;

van Herpen, Carla M. L. ;

Saura, Cristina ;

Thistiethwaite, Fiona ;

Lord, Simon ;

Moreno, Victor ;

Macpherson, Iain R. ;

Boni, Valentina ;

Rolfo, Christian ;

de Vries, Elisabeth G. E. ;

Rottey, Sylvie ;

Geenen, Jilt ;

Eskens, Ferry ;

Gil-Martin, Marta ;

Mommers, Ellen C. ;

Koper, Norbert P. ;

Aftimos, Philippe .

LANCET ONCOLOGY, 2019, 20 (08) :1124-1135

[3] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

[4] IGF binding proteins in cancer: mechanistic and clinical insights [J].

Baxter, Robert C. .

NATURE REVIEWS CANCER, 2014, 14 (05) :329-341

[5] A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].

Berns, Katrien ;

Horlings, Hugo M. ;

Hennessy, Bryan T. ;

Madiredjo, Mandy ;

Hijmans, E. Marielle ;

Beelen, Karin ;

Linn, Sabine C. ;

Gonzalez-Angulo, Ana Maria ;

Stemke-Hale, Katherine ;

Hauptmann, Michael ;

Beijersbergen, Roderick L. ;

Mills, Gordon B. ;

de Vijver, Marc J. van ;

Bernards, Rene .

CANCER CELL, 2007, 12 (04) :395-402

[6] CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity [J].

Burr, Marian L. ;

Sparbier, Christina E. ;

Chan, Yih-Chih ;

Williamson, James C. ;

Woods, Katherine ;

Beavis, Paul A. ;

Lam, Enid Y. N. ;

Henderson, Melissa A. ;

Bell, Charles C. ;

Stolzenburg, Sabine ;

Gilan, Omer ;

Bloor, Stuart ;

Noori, Tahereh ;

Morgens, David W. ;

Bassik, Michael C. ;

Neeson, Paul J. ;

Behren, Andreas ;

Darcy, Phillip K. ;

Dawson, Sarah-Jane ;

Voskoboinik, Ilia ;

Trapani, Joseph A. ;

Cebon, Jonathan ;

Lehner, Paul J. ;

Dawson, Mark A. .

NATURE, 2017, 549 (7670) :101-105

[7] Targeting G protein-coupled receptor signalling by blocking G proteins [J].

Campbell, Adrian P. ;

Smrcka, Alan V. .

NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (11) :789-803

[8] Heme Oxygenase-1-Mediated Autophagy Protects Against Hepatocyte Cell Death and Hepatic Injury from Infection/Sepsis in Mice [J].

Carchman, Evie H. ;

Rao, Jayashree ;

Loughran, Patricia A. ;

Rosengart, Matthew R. ;

Zuckerbraun, Brian S. .

HEPATOLOGY, 2011, 53 (06) :2053-2062

[9] Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer [J].

Castagnoli, L. ;

Ghedini, G. C. ;

Koschorke, A. ;

Triulzi, T. ;

Dugo, M. ;

Gasparini, P. ;

Casalini, P. ;

Palladini, A. ;

Iezzi, M. ;

Lamolinara, A. ;

Lollini, Pl ;

Nanni, P. ;

Chiodoni, C. ;

Tagliabue, E. ;

Pupa, S. M. .

ONCOGENE, 2017, 36 (12) :1721-1732

[10] Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J].

Chan, Arlene ;

Delaloge, Suzette ;

Holmes, Frankie A. ;

Moy, Beverly ;

Iwata, Hiroji ;

Harvey, Vernon J. ;

Robert, Nicholas J. ;

Silovski, Tajana ;

Gokmen, Erhan ;

von Minckwitz, Gunter ;

Ejlertsen, Bent ;

Chia, Stephen K. L. ;

Mansi, Janine ;

Barrios, Carlos H. ;

Gnant, Michael ;

Buyse, Marc ;

Gore, Ira ;

Smith, John, II ;

Harker, Graydon ;

Masuda, Norikazu ;

Petrakova, Katarina ;

Guerrero Zotano, Angel ;

Iannotti, Nicholas ;

Rodriguez, Gladys ;

Tassone, Pierfrancesco ;

Wong, Alvin ;

Bryce, Richard ;

Ye, Yining ;

Yao, Bin ;

Martin, Miguel .

LANCET ONCOLOGY, 2016, 17 (03) :367-377

← 1 2 3 4 5 6 7 8 9 10 →